Matthew Rosebraugh
Overview
Explore the profile of Matthew Rosebraugh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
208
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Savaryn J, Smith R, Rosebraugh M, Neenan M, Burton R, Marsh K, et al.
Pharmacol Res Perspect
. 2024 Apr;
12(2):e1190.
PMID: 38597598
Analysis was conducted to compare levodopa/carbidopa pharmacokinetics and drug-related material in plasma of healthy participants after receiving a continuous infusion of Levodopa/Carbidopa Intestinal Gel (LCIG) to a continuous subcutaneous infusion...
2.
Rosebraugh M, Neenan M, Facheris M
Clin Pharmacol Drug Dev
. 2022 Nov;
12(4):407-415.
PMID: 36394144
This phase 1 study assessed the safety, tolerability, and pharmacokinetics of a single 24-hour continuous subcutaneous dose of foslevodopa/foscarbidopa in healthy adult Japanese (N = 24), Han Chinese (N =...
3.
Rosebraugh M, Stodtmann S, Liu W, Facheris M
Parkinsonism Relat Disord
. 2022 Mar;
97:68-72.
PMID: 35339102
Introduction: The objective of this study was to compare the pharmacokinetics (PK) of levodopa (LD) from 24-h continuous subcutaneous infusion of foslevodopa/foscarbidopa to the LD pharmacokinetics from 16-h levodopa-carbidopa intestinal...
4.
Rosebraugh M, Liu W, Neenan M, Facheris M
J Parkinsons Dis
. 2021 Aug;
11(4):1695-1702.
PMID: 34366380
Background: Foslevodopa/foscarbidopa, formerly known as ABBV-951, is a formulation of levodopa/carbidopa prodrugs with solubility that allows for subcutaneous (SC) infusion and is in development for the treatment of motor complications...
5.
Rosebraugh M, Voight E, Moussa E, Jameel F, Lou X, Zhang G, et al.
Ann Neurol
. 2021 Mar;
90(1):52-61.
PMID: 33772855
Objective: The aim was to demonstrate that continuous s.c. infusion of a soluble levodopa (LD)/carbidopa (CD) phosphate prodrug combination effectively delivers stable LD exposure via a minimally invasive and convenient...
6.
Oberoi R, Zhao W, Rosebraugh M, Mensa F, Wang H, Liu W
Clin Ther
. 2020 Jul;
42(7):1317-1329.
PMID: 32622784
Purpose: Fixed-dose combination glecaprevir (GLE) 300 mg + pibrentasvir (PIB) 120 mg is an orally administered once daily antiviral regimen approved for the treatment of hepatitis C virus (HCV) infection....
7.
Rosebraugh M, Kalluri H, Liu W, Locke C, Sidhu D, Han J, et al.
Pharmacol Res Perspect
. 2019 Apr;
7(2):e00473.
PMID: 30977301
A new levodopa-carbidopa intestinal gel (LCIG) system featuring a higher levodopa/carbidopa (LD/CD) concentration and viscosity, LCIG-HV, is being developed to reduce the intrajejunal volume of LD/CD that is administered as...
8.
Parmentier J, Voss J, Graff C, Schwartz A, Argiriadi M, Friedman M, et al.
BMC Rheumatol
. 2019 Mar;
2:23.
PMID: 30886973
Background: Anti-cytokine therapies such as adalimumab, tocilizumab, and the small molecule JAK inhibitor tofacitinib have proven that cytokines and their subsequent downstream signaling processes are important in the pathogenesis of...
9.
Othman A, Rosebraugh M, Chatamra K, Locke C, Dutta S
J Parkinsons Dis
. 2017 Feb;
7(2):275-278.
PMID: 28211816
In a double-blind, double-dummy, double-titration Phase 3 trial in advanced Parkinson's disease (PD) patients, the efficacy and safety of Levodopa-carbidopa intestinal gel (LCIG) infusion were characterized relative to immediate-release oral...
10.
Rosebraugh M, Widness J, Veng-Pedersen P
Drug Metab Dispos
. 2011 Apr;
39(7):1214-20.
PMID: 21460232
The primary objective of this work was to determine the optimal time for administration of an erythropoietin (Epo) dose to maximize the erythropoietic effect using a simulation study based on...